QELBREE is a Oral Capsule, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Supernus Pharmaceuticals, Inc. The primary component is Viloxazine Hydrochloride.
Product ID | 17772-132_bfca3279-8f36-5bb2-e053-2995a90a23a5 |
NDC | 17772-132 |
Product Type | Human Prescription Drug |
Proprietary Name | QELBREE |
Generic Name | Viloxazine Hydrochloride |
Dosage Form | Capsule, Extended Release |
Route of Administration | ORAL |
Marketing Start Date | 2021-04-02 |
Marketing Category | NDA / |
Application Number | NDA211964 |
Labeler Name | Supernus Pharmaceuticals, Inc |
Substance Name | VILOXAZINE HYDROCHLORIDE |
Active Ingredient Strength | 150 mg/1 |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-04-02 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
17772-131 | QELBREE | viloxazine hydrochloride |
17772-132 | QELBREE | viloxazine hydrochloride |
17772-133 | QELBREE | viloxazine hydrochloride |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
QELBREE 88696469 not registered Live/Pending |
Supernus Pharmaceuticals, Inc. 2019-11-18 |